Alpha-lipoic acid (ALA) and Calf Blood Hemodialysate improve sciatic nerve regeneration in mice, with ALA showing superior benefits.

Despite advances in microsurgical techniques, peripheral nerve injuries frequently lead to incomplete functional recovery and long-term disability, representing a significant unmet clinical need. Current treatments often fall short, necessitating adjunctive pharmacological strategies to enhance regenerative outcomes. This study investigates two promising agents: Calf Blood Hemodialysate (Actovegin), a deproteinized ultrafiltrate rich in low-molecular-weight peptides and metabolites, known for its metabolic support and neurotrophic properties, and alpha-lipoic acid (ALA), a potent mitochondrial antioxidant and metabolic modulator. Both are explored for their potential to support nerve repair and functional restoration.

Adult C57BL/6 mice underwent a standardized sciatic nerve crush injury model. Animals were randomized into four groups: untreated controls, Calf Blood Hemodialysate (Actovegin) 200 mg/kg/day treated, alpha-lipoic acid (ALA) 20 mg/kg/day treated, and a combination therapy group. Treatment commenced 48 hours post-operatively. Calf Blood Hemodialysate was administered intraperitoneally (IP) for 10 days, while ALA was delivered IP for 14 days. Functional recovery was meticulously assessed over a 50-day period using electromyography, the Basso Mouse Scale for locomotor function, and the Beam Walk Test. Immunohistochemical evaluation included analysis of muscle morphology and spinal cord glial fibrillary acidic protein (GFAP) expression.

Both monotherapies, Calf Blood Hemodialysate and ALA, significantly improved neuromotor performance and electrophysiological outcomes when compared to untreated controls. The observed improvements suggest a therapeutic effect on nerve regeneration and functional restoration.

ALA, however, exhibited superior histological and functional benefits, promoting earlier and more sustained recovery compared to Calf Blood Hemodialysate. This indicates a more robust and lasting regenerative effect with ALA treatment. While both agents showed promise individually, combined administration of Calf Blood Hemodialysate and ALA did not produce synergistic effects, suggesting their mechanisms might not be complementary in this context or that optimal dosing for synergy was not achieved. The histological findings, including muscle morphology and spinal cord GFAP expression, further supported ALA's superior regenerative capacity.